• To the best of our knowledge, this sophisticated coagulation assessment has not been performed to characterise thrombotic changes in the transcatheter aortic valve implantation (TAVI) setting, nor have the two latest iteration cartridge-based systems been directly compared in the elective perioperative period. (bmj.com)
  • Current intraoperative antithrombotic regimes for patients undergoing transcatheter aortic valve implantation (TAVI) are based on data and strategies extrapolated from percutaneous coronary intervention. (bmj.com)
  • The first-in-human Edwards-Cribier valve was implanted by Prof. Alain Cribier in 2002 showing the feasibility of TAVI concept. (heartvalves.com)
  • As Edwards received the CE Mark for SAPIEN valve in 2007, 2 the company has set the stage to continue innovating in TAVI, bringing new technologies with improved clinical outcomes. (heartvalves.com)
  • Continues to elevate Edwards' TAVI valve performance, with further reductions in paravalvular leak (PVL) 7 and low permanent pacemaker implantation rates, 8 through improved design features. (heartvalves.com)
  • When the first valve choice matters, the SAPIEN 3 platform is designed to deliver a reliable TAVI experience so patients can live their best lives. (heartvalves.com)
  • Many patients are unsuitable for conventional femoral transcatheter aortic valve implantation (TAVI) but there is limited evidence as to which alternative approach has the best outcomes. (biomedcentral.com)
  • Over the last two decades, the treatment of aortic valve stenosis has changed significantly with transcatheter aortic valve implantation (TAVI) becoming widely used in symptomatic elderly patients with high surgical risk. (biomedcentral.com)
  • Aim of the study was to find predictors of allocating patients after transcatheter aortic valve implantation (TAVI) to geriatric (GR) or cardiac rehabilitation (CR) and describe this new patient group based on a differentiated characterization. (biomedcentral.com)
  • For patients having a prohibitive surgical risk, transcatheter aortic valve implantation (TAVI) has been developed as an alternative to the surgical valve replacement. (biomedcentral.com)
  • ranscatheter aortic valve implantation (TAVI) has gained wide acceptance for the treatment of severe aortic stenosis among patients deemed to be at increased risk for surgical aortic valve replacement. (123dok.net)
  • Over the past two decades, transcatheter aortic valve implantation (TAVI) has been established as a viable alternative treatment to deal with severe aortic stenosis in patients at risk of open-heart surgery. (frontiersin.org)
  • Foremost in the development of percutaneous treatment options for aortic valve stenosis, transcatheter aortic valve implantation (TAVI) has improved the treatment options for elderly patients with aortic valve stenosis. (bmj.com)
  • Transcatheter aortic valve implantation (TAVI) is the treatment of choice in patients with symptomatic severe aortic stenosis who are either inoperable or at high risk for conventional surgical aortic valve replacement. (icrjournal.com)
  • Transcatheter aortic valve implantation (TAVI) has emerged as an alternative treatment for symptomatic severe aortic stenosis in patients deemed to be at high operative risk for conventional surgical aortic valve replacement (SAVR). (icrjournal.com)
  • Transcatheter aortic valve implantation (TAVI) has become an established treatment for patients with severe aortic valve stenosis (AS) who are inoperable or at high surgical risk1-6, and an attractive alternative in intermediate surgical-risk patients7,8. (heartvascularcentre.com)
  • Due to her high surgical risk, TAVI was chosen as the preferred treatment option by the local Heart Team despite a lack of leaflet or annular calcification, and a SAPIEN 3 valve (Edwards Lifesciences) was successfully implanted without paravalvular leak and with satisfactory valve function at six months. (heartvascularcentre.com)
  • In this author's experience of seven cases of rheumatic AS (unpublished data), TAVI, using either the SAPIEN or CoreValve (Medtronic, Minneapolis, MN, USA) prostheses, was successful in all cases with durable results at one year. (heartvascularcentre.com)
  • The 1-year follow-up analysis of the doubly randomized SOLVE-TAVI trial uncovered no reason, necessarily, to prefer either of two recent-generation valve prostheses for transcatheter aortic-valve replacement (TAVR or TAVI) over the other in patients at high to intermediate surgical risk. (medscape.com)
  • No significant difference in the composite primary endpoint, the only outcome for which the trial was sufficiently powered, was seen between the Corevalve Evolut R (Medtronic), a self-expandable valve (SEV), and the Sapien 3 (Edwards Lifesciences), a balloon-expandable valve (BEV), at 12 months, consistent with and extending the previously published SOLVE-TAVI 30-day results . (medscape.com)
  • Objectives Transcatheter aortic valve implantation (TAVI) is an established treatment for patients with severe symptomatic aortic stenosis. (bmj.com)
  • 5 For patients with severe symptomatic aortic stenosis (AS), valvular replacement has been increasingly performed via a femoral catheter technique called transcatheter aortic valve implantation (TAVI). (bmj.com)
  • General agreement on the best anesthetic management of patients undergoing transcatheter aortic valve implantation (TAVI) is lacking. (shda.org.au)
  • This report summarises some key sessions on transcatheter aortic valve implantation (TAVI), valve-in-valve (ViV) interventions and optimisation of such procedures. (hospitalhealthcare.com)
  • BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a treatment option for high-risk patients with severe aortic stenosis. (ox.ac.uk)
  • Results from the SAVI-TF Registry 1 , which was recently published in JACC: Cardiovascular Interventions , show that the ACURATE neo (Boston Scientific) transcatheter aortic valve implantation (TAVI) device is associated with favourable clinical and echocardiographic outcomes at one year (8% mortality, 2.3% disabling stroke, and 9.9% pacemaker rate). (cardiovascularnews.com)
  • compared outcomes of patients with small aortic annuli who underwent TAVI with the ACURATE neo with those who underwent TAVI with SAPIEN 3 (Edwards Lifesciences). (cardiovascularnews.com)
  • In structural heart interventions, my research assessed novel approaches in transcatheter aortic valve implantation (TAVI) as high valve implantation and bioprosthetic valve modification during valve-in-valve TAVI. (wikidoc.org)
  • Transcatheter aortic valve implantation (TAVI) has been adopted rapidly in Europe. (biomedcentral.com)
  • The review focused on the comparison of the following TAVI strategies: transfemoral (TF) and transapical (TA) SAPIEN and CoreValve implantation. (biomedcentral.com)
  • Seven European national TAVI registries (UK, Swiss, Belgium, Italy, Spain, France, Germany) were identified, including a total of 9786 patients who received TF-SAPIEN ( n = 2885), TA-SAPIEN ( n = 2252) and CoreValve ( n = 4649) implantation. (biomedcentral.com)
  • The German registry has the highest mortality for every TAVI strategy amongst all other European registries and especially for the TA-SAPIEN group. (biomedcentral.com)
  • The aim of this study is to obtain an insight into the role of TAVI in the treatment of high-risk patients with aortic stenosis in Europe by conducting a meta-analysis of European national registries, focusing on the three most commonly used TAVI procedures : the transfemoral and transapical balloon-expandable Edwards SAPIEN transcatheter heart valve (Edwards Lifesciences, Irvine, CA, USA) and the self-expanding Medtronic CoreValve (Medtronic, Minneapolis, MN, USA). (biomedcentral.com)
  • 2) TAVI procedures should have been performed using transfemoral (TF SAPIEN) and/or transapical (TA SAPIEN) balloon-expandable Edwards SAPIEN transcatheter heart valve and/or self-expanding Medtronic CoreValve. (biomedcentral.com)
  • Moderate or severe paravalvular leak (PVL) following transcatheter aortic valve implantation (TAVI) has been associated with worse outcomes. (recintervcardiol.org)
  • 9. Data on file at Edwards Lifesciences. (heartvalves.com)
  • Our group has previously demonstrated that, in a patient with systemic lupus erythematosus-associated AS (where the pathology was leaflet thickening without valve calcification), a SAPIEN XT valve (Edwards Lifesciences, Irvine, CA, USA) was implanted in a stable position12. (heartvascularcentre.com)
  • Results from the PARTNER 2, Cohort A trial showed that death or disabling stroke at 2 years-the trial's primary endpoint-were not significantly different for patients randomized to TAVR using the Sapien XT (Edwards Lifesciences) or open-heart surgery. (tctmd.com)
  • Early data suggest that stroke rates are even lower with the lower-profile Sapien 3 device (Edwards Lifesciences), which is the subject of another late-breaking clinical trial presentation tomorrow, also in intermediate-risk patients. (tctmd.com)
  • The first-generation ACURATE neo struggled with rates of more-than-mild PVL approached 11% in the NEOPRO Registry and failed to prove noninferiority against Edwards Lifesciences' Sapien 3 and Medtronic's CoreValve Evolut valves in the SCOPE I and SCOPE II trials, where its leak rates were thrice as high as the competition. (worldmedicinefoundation.com)
  • He was previously employed by Edwards Lifesciences, LLC. (vivitrolabs.com)
  • The need for new permanent pacemaker implantation was more frequent among patients treated with the LOTUS valve. (123dok.net)
  • Transcatheter aortic valve replacement had positive clinical and hemodynamic results, when comparing pre-and post-procedure, and the hemodynamic profile of the prosthesis was sustained throughout follow-up. (rbccv.org.br)
  • Measured or predicted patient-prosthesis mismatch following aortic valve replacement. (wikidoc.org)
  • In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable TAVR: the S3U registry. (heartvalves.com)
  • If one disregards the financial considerations, predictability of the procedural outcome and certainty regarding the durability of TAVR prostheses are 2 of the main remaining restrictions to universal implementation. (ahajournals.org)
  • At a quaternary academic cardiac surgery center with a well-established structural heart program, patients undergoing isolated SAVR in the post-TAVR era had lower STS PROM, more implantation of bioprosthetic valves, utilization of larger valves, annular enlargement, and lower in-hospital mortality. (emory.edu)
  • In this study, transapical transcatheter mitral valve-in-valve implantation (TAMVI) was compared with surgical redo mitral valve replacement (SRMVR) in terms of clinical outcomes. (frontiersin.org)
  • Transapical transcatheter mitral valve-in-valve implantation (TAMVI) is now regarded as a promising alternative treatment for patients with degenerated bioprosthesis or failed annuloplasty ( 3 ). (frontiersin.org)
  • Concomitant transapical treatment of aortic stenosis and degenerated mitral bioprosthesis with two 29 mm Edwards Sapien XT prostheses. (nih.gov)
  • Implantation of prosthetic cardiac valves to treat hemodynamically significant aortic or mitral valve disease has become increasingly common. (medscape.com)
  • Results: Twenty-one patients with a annuloplasty or valve prosthesis-protected mitral annulus underwent tip-to-base LAMPOON (19 preventive, 2 rescue). (emory.edu)
  • Three-year outcomes of balloon-expandable transcatheter aortic valve implantation accor ding to annular size. (wikidoc.org)
  • A case of combined aortic bioprosthetic valve degeneration and patient-prosthesis mismatch during pregnancy: decision-making and implications after pregnancy. (nih.gov)
  • No randomised trial-at least, not one with published results-has directly compared ACURATE neo with valves such as SAPIEN 3 or CoreValve (Medtronic), but SAVI-TF does provide some insight into how it measures up against other valves. (cardiovascularnews.com)
  • In fact, Kim observes that the one-year mortality (8%) seen with ACURATE neo in SAVI-TF is "much lower" than that seen in post-market registries both for SAPIEN 3 (12% in the SOURCE 3 registry) and for CoreValve (16 % in the Advance registry). (cardiovascularnews.com)
  • Since Edwards was founded in 1958, our focus has always been on improving the quality of life of every patient that all our valves treat. (heartvalves.com)
  • Self-expanding Medtronic Evolut R valves were used in 84% of TS procedures, while balloon-expandable Edwards SAPIEN valves were used in all TA procedures. (biomedcentral.com)
  • Predictors of procedural success in patients with degenerated surgical valves undergoing transcatheter aortic valve-in-valve implantation. (wikidoc.org)
  • Durability of bioprosthetic surgical aortic valves in patients who underwent transcatheter valve-in-valve implantation. (wikidoc.org)
  • currently the SAPIEN 3) with subsequent introduction of the self-expanding Evolut R (Medtronic, Minneapolis, MN) in 2015 (Fig. 1 ). (biomedcentral.com)
  • Also pacemaker implantation is a commonly performed invasive cardiology procedure at Electrophysiology Pacemaker Laboratory of our Center. (groupflorence.com)
  • VARC-3 technical success rates were similar in the ACURATE neo2 and ACURATE neo groups (97.6% vs 95.1%), as were in-hospital permanent pacemaker implantations (7.6% vs 9.1%), strokes (2 each), and all-cause deaths (3 vs 1). (worldmedicinefoundation.com)
  • Regardless, it is remarkable that the relatively small modification of adding a sealing skirt in the NEO2 generation of this prosthesis effectuates such a considerable reduction of PVR as shown in the present study," they say. (worldmedicinefoundation.com)
  • We evaluated PVL after ACURATE neo and neo2 implantation, and the role of AV calcification. (recintervcardiol.org)
  • Logistic regression model identified age, previous coronary stent implantation, coronary artery bypass grafting + heart valve surgery, ≥ 2 combined heart valve surgery and hospital-acquired infection as independent predictors of AD. (bvsalud.org)
  • Methods and Results--All patients undergoing transcatheter aortic valve implantation with the Edwards SAPIEN 3 or the LOTUS valve system were included into the Swiss Transcatheter Aortic Valve Implantation Registry. (123dok.net)
  • A recent report from the German Heart Surgery Registry showed that the number of mechanical prostheses has reduced considerably over the last decade, and a shift towards biological implantation has been seen. (hospitalhealthcare.com)
  • Differences in peri-procedural indices reflect the disparate patient populations and factors governing prosthesis choice, and short- and long-term mortality was similar. (biomedcentral.com)
  • Measures of ventilatory efficiency are prognostic of mortality in patients who may require transcatheter pulmonary valve implantation (TPVI), and speckle-tracking echocardiographic (STE) measures of RV function appear to improve after TPVI. (shda.org.au)
  • The 5 year durability data for the SAPIEN device look very good. (vivitrolabs.com)
  • PARTNER 2A randomized 2,032 intermediate-risk patients with severe symptomatic aortic stenosis at one of 57 centers to either open surgical valve replacement or transcatheter aortic valve implantation with the Sapien XT. (tctmd.com)
  • Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis. (heartvalves.com)
  • Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. (heartvalves.com)
  • The safety and effectiveness of the fully repositionable LOTUS valve system as compared with the balloon-expandable Edwards SAPIEN 3 prosthesis for the treatment of aortic stenosis has not been evaluated to date. (123dok.net)
  • One of the most important new treatment options is the percutaneous treatment for aortic valve stenosis (transcatheter aortic valve implantation), since aortic valve disease is a rather common problem in elderly patients, with many of them at high risk for surgery. (bmj.com)
  • Transcatheter aortic valve implantation in rheumatic aortic stenosis. (heartvascularcentre.com)
  • Real-World Experience With the SAPIEN 3 Ultra Transcatheter Heart Valve: A Propensity-Matched Analysis From the United States. (heartvalves.com)
  • The trial raised a few red flags, including a stroke rate that was increased seven times for patients who received the balloon-expandable Sapien 3 valve compared to the SEV. (medscape.com)
  • Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes. (ox.ac.uk)
  • The first-generation Edwards SAPIEN valve was introduced as a lifesaving treatment option for inoperable and high surgical risk patients. (heartvalves.com)
  • It provides considerations, recommendations and sample protocols for the timing of echocardiography during patient selection, device implantation, and postoperative care. (shda.org.au)
  • These results emphasise the need of careful prosthesis selection in each individual patient," Mauri et al . (cardiovascularnews.com)
  • Conclusions--The repositionable LOTUS valve system and the balloon-expandable Edwards SAPIEN 3 prosthesis appeared comparable in regard to the Valve Academic Research Consortium-2 early safety outcome, and the rates of more than mild aortic regurgitation were exceedingly low for both devices. (123dok.net)